Last reviewed · How we verify
NCT05983380
The Effect of Hand Exercises on Upper Limb Volume, Quality of Life, and Hand Function in Breast Cancer Survivors
NA trial testing Hand Mobility and Grip Strengthening Exercises in Breast Cancer Lymphedema in 50 participants. Currently enrolling.
30 September 2024
Quick facts
| Lead sponsor | Texas Woman's University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 October 2023 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Hand Mobility and Grip Strengthening Exercises
- Usual Care
Conditions studied
- Breast Cancer Lymphedema — all drugs for Breast Cancer Lymphedema →
Sponsor
Texas Woman's University
Who can join
18 and older, female only, with Breast Cancer Lymphedema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether the addition of simple hand mobility and grip strengthening exercises to the usual care for upper extremity lymphedema will reduce limb volume and improve the quality of life, hand dexterity, and grip strength for those experiencing breast cancer-related lymphedema. Researchers will compare those receiving the usual treatment to those receiving the usual treatment plus hand mobility and grip strengthening exercises.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05983380
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Lymphedema
Currently open trials in the same condition.
- NCT07420725 — The Relationship Between Gait Parameters and Balance Disorder and Fall Risk in Breast Cancer-Related Lymphedema(BCRL) · active not recruiting
- NCT06302361 — Lymphovenous Anastomosis for Breast Cancer Lymphedema · NA · active not recruiting
- NCT05725265 — LLLT for BCRL: a Randomized, Placebo-controlled Study · NA · recruiting
- NCT05441943 — Lymphaticovenous Anastomosis as Treatment for Lymphedema · NA · active not recruiting
- NCT05120180 — Effect of ALND With Vein Branches Reservation on Postoperative Upper Limb Edema and Dysfunction in Breast Cancer · NA · active not recruiting
Other Texas Woman's University trials
Trials by the same sponsor.
- NCT05074849 — Benefits of Insoles With Real-Time Alert and Foot Self-Care Education · NA · not yet recruiting
- NCT07493954 — Eat Healthy Grow Healthy Program to Promote Fruit and Vegetable Intake in Preschoolers · NA · active not recruiting
- NCT07020897 — Short-term and Intermediate-term Effects of Self-applied Joint Mobilization Versus Clinician-applied Joint Mobilization · NA · not yet recruiting
- NCT07130539 — Mediterranean-DASH Intervention for Neurodegenerative Delay and High-Intensity Interval Training in Adults With Hyperten · NA · active not recruiting
- NCT06705634 — How Dry Needling at the Neck Affects Shoulder Movement, Strength, Pain, and Shoulder Circulation · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05983380 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Texas Woman's University
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05983380.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing